A Phase 1, Open‑Label, Three Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Tablet Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloid polyneuropathy; Cardiomyopathies
- Focus Pharmacokinetics
- Sponsors Pfizer
- 26 Jul 2016 Status changed from recruiting to completed.
- 05 May 2016 Status changed from not yet recruiting to recruiting.
- 09 Mar 2016 New trial record